Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines

作者：Liu, Yang; Lu, Jie; Zhang, Zhimeng; Zhu, Lin; Dong, Shicai; Guo, Gaochao; Li, Ruohong; Nan, Yang; Yu, Kai; Zhong, Yue; Huang, Qiang^*

来源：Cell Death & Disease, 2017, 8(8): e3022.

DOI：10.1038/cddis.2017.396

• B-KINASE-EPSILON
• IKK-EPSILON
• IN-VITRO
• CANCER
• YAP
• DROSOPHILA
• PROLIFERATION
• EXPRESSION
• TARGET
• BRAIN

Glioblastoma multiforme (GBM) is the most prevalent form of malignant brain tumor. Amlexanox, a novel compound, has been shown to have anti-cancer potential. In this study, the anti-tumoral effects and the underlying mechanisms of amlexanox were investigated. Amlexanox significantly suppressed proliferation and invasion and induced apoptosis in glioblastoma cells. Furthermore, we found that amlexanox altered the protein expression of the Hippo pathway by downregulating IKBKE. Our data indicates that IKBKE directly targets LATS1/2 and induces degradation of LATS1/2, thereby inhibiting the activity of the Hippo pathway. In vivo results further confirmed the tumor inhibitory effect of amlexanox via the downregulation of IKBKE, and amlexanox induced no apparent toxicity. Collectively, our studies suggest that amlexanox is a promising therapeutic agent for the treatment of GBM.

• 出版日期2017-8
• 单位聊城市人民医院; 山东省千佛山医院; 天津医科大学